- Pentoxifylline improves altered blood flow properties by its influence on pathologically impaired red cell deformability, by inhibiting platelet aggregation and by reducing increased viscosity.
- Pentoxifylline enhances the nutritive microcirculation in areas with impaired blood flow
- Pentoxifylline increases the 3'5'-cyclic AMP of brain tissue. This metabolic action could influence brain function which shown by electroencephalography.
- For peripheral occlusive arterial disease and arteriovenous disorders of an arteriovenous disorders of an arteriosclerosis or diabetic nature (e.g. arteriosclerosis with intermittent claudication or rest pain, diabetic angiopathy) and trophic distrubances (post thrombotic syndrome, leg ulcer and gangrene).
- Vascular distrubances of the eye (acute, subacute and chronic impairment of retinal and choroidal perfusion)
- Cerebral circulatory disorders (sequel of cerebral arteriosclerosis such as difficulties in concentrain, vertigo, impairment of memory) ischaemic and post apoplectic states.
- Pentoxifylline is not recommended to patient with hypersensitivity to pentoxifylline, cerebral or extensive retinal haemorrhage, or myocardial infarction
- Pentoxifylline should not be used during pregnancy
- Severe coronary and cerebral sclerosis with hypertension, and severe cardiac arrhythmmias are relative contra-indications for a parenteral treatment
- Pentoxifylline should not be administered to patients intolerance to methylxantine derivates such as coffein, theophyllin and theobromine.
Gastrointestinal: nausea, vomiting,
